What Can Investors Expect From Immunogen (IMGN) Shares After Piper Jaffray’s New Coverage?

September 8, 2018 - By Megan Stone

ImmunoGen, Inc. (NASDAQ:IMGN) Logo

Investors sentiment decreased to 0.95 in Q1 2018. Its down 0.43, from 1.38 in 2017Q4. It worsened, as 24 investors sold ImmunoGen, Inc. shares while 59 reduced holdings. 35 funds opened positions while 44 raised stakes. 102.59 million shares or 1.04% more from 101.53 million shares in 2017Q4 were reported.

Td Asset Mgmt invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). 1.79 million were reported by Wells Fargo Mn. Bancorp Of America Corp De reported 996,801 shares or 0% of all its holdings. Citadel Advsr Ltd reported 0% stake. Zurcher Kantonalbank (Zurich Cantonalbank) reported 11,144 shares. Natixis Advsr L P invested in 237,072 shares. Ghost Tree Cap Lc has 0.05% invested in ImmunoGen, Inc. (NASDAQ:IMGN). Bancorp Of Ny Mellon Corp invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN). Amalgamated Natl Bank stated it has 0% of its portfolio in ImmunoGen, Inc. (NASDAQ:IMGN). Comerica Commercial Bank accumulated 18,369 shares or 0% of the stock. Royal Natl Bank Of Canada has 130,388 shares. Northeast Finance Consultants accumulated 0.12% or 34,315 shares. Stratos Wealth Partners Ltd holds 0% or 1,105 shares. California State Teachers Retirement Systems holds 0% or 152,115 shares in its portfolio. The Ontario – Canada-based Manufacturers Life Insurance The has invested 0% in ImmunoGen, Inc. (NASDAQ:IMGN).

Since March 15, 2018, it had 0 buys, and 3 selling transactions for $525,905 activity. Another trade for 25,000 shares valued at $300,405 was made by JUNIUS DANIEL M on Friday, March 16.

How Piper Jaffray Currently Rates Immunogen (IMGN)

In analysts note issued to clients on 7 September, research analysts at Piper Jaffray has initiated coverage on Immunogen (IMGN) shares. The financial company issued a key “Overweight” rating for IMGN stock.

The stock increased 0.32% or $0.03 during the last trading session, reaching $9.35. About 1.52 million shares traded. ImmunoGen, Inc. (IMGN) has risen 105.72% since September 8, 2017 and is uptrending. It has outperformed by 93.15% the S&P500.

Analysts await ImmunoGen, Inc. (NASDAQ:IMGN) to report earnings on November, 2. They expect $-0.30 EPS, up 18.92 % or $0.07 from last year’s $-0.37 per share. After $-0.30 actual EPS reported by ImmunoGen, Inc. for the previous quarter, Wall Street now forecasts 0.00 % EPS growth.

ImmunoGen, Inc., a clinical-stage biotechnology company, develops targeted anticancer therapeutics. The company has market cap of $1.39 billion. The firm develops its products using its antibody-drug conjugate technology. It currently has negative earnings. The companyÂ’s product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha for the treatment of platinum-resistant ovarian cancer; IMGN529, an ADC that is in Phase 1b/2 clinical trials for B-cell malignancies; coltuximab ravtansine, which is in Phase 2 trials for B-cell malignancies; IMGN779 that is in Phase 1 clinical trials for the treatment of acute myeloid leukemia (AML); and IMGN632, a preclinical CD123-targeting ADC for the treatment of hematological malignancies, including AML.

Another recent and important ImmunoGen, Inc. (NASDAQ:IMGN) news was published by Seekingalpha.com which published an article titled: “Premarket analyst action – healthcare” on September 07, 2018.

ImmunoGen, Inc. (NASDAQ:IMGN) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.